Posted by Michael Wonder on 29 Jun 2020
Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options
29 June 2020 - Novartis Pharma today announced that the Japanese Ministry of Health, Labour and Welfare simultaneously approved five new treatment options for Japanese patients:
- Tabrecta (capmatinib) an oral MET inhibitor for MET exon 14 skipping mutation positive advanced and/or recurrent unresectable non-small cell lung cancer
- Entresto (sacubitril valsartan sodium hydrate) in chronic heart failure
- Mayzent (siponimod fumaric acid) in secondary progressive multiple sclerosis
- Enerzair (glycopyrronium bromide, indacaterol acetate, mometasone furoate)
- Atectura (indacaterol acetate, mometasone furoate) in different forms of asthma
